Related posts

Tech fades in mixed tradingStocks, oil and cryptos rallyOil slides, but stocks hold on China’s weakness
Investor Insights

This summary was created by AI, based on 4 opinions in the last 12 months.

Gilead Sciences Inc. has a mixed outlook from various experts. One reviewer expresses skepticism about investing due to the company's reliance on blockbuster drugs with impending patent expirations, while another highlights a turnaround with accelerating earnings driven by their HIV platform. Another review mentions the stock hitting 52-week highs and appreciates the recent performance, noting a breakout after years of consolidation, though the reviewer remains unsure if this breakout will sustain. However, there is a contrasting opinion that suggests the stock may be overvalued despite a recent bounce back in share prices. Overall, the perspectives indicate a blend of optimism about growth potential, especially in HIV treatments, but caution regarding valuation and long-term viability.

Consensus
Mixed
Valuation
Overvalued
DON'T BUY

He had owned it for 10 years at a time when it had a blockbuster drug that cured hepatitis. Gilead took profits and invested them into HIV drugs. As with other drug companies holding patents on blockbuster drugs with expiry dates, don't buy this one.

BUY

He waited a long time to see performance, but patience paid off. Earnings are accelerating, fueled by their HIV platform.

WATCH

Hitting 52-week highs. Caught his attention because last week they beat top and bottom lines. After consolidating 9 years, it's starting to break out. Doesn't know this well enough to see if this breakout will hold, but worth watching.

PARTIAL SELL

The business isn't worth as much as the stock is selling, even though shares have recently bounced back.

DON'T BUY

High flyer because of Hep C, so successful it isn't needed on an ongoing basis. Its HIV drug was equally successful. Ironically, success impacted growth of those drugs negatively. Decent dividend. 

BUY

Healthcare is down 2% year. He likes the devices in HC, with Stryker his top pick. Surgeries are coming back, and the company has a new suite of products coming.

BUY
Was upgraded today

It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming. 

HOLD

Chart pattern indicating weakness in the company.
Risk lower than the past year.
$60 share price a good time to buy. 

WATCH

In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky. 

BUY

Has long owned this, because it's a value stock and keeps raising its dividend.

WAIT

It is a biotech company well known for a cure for Hepatitis C which is off patent now. It made several acquisitions and has built out an HIV franchise. He needs to see execution on the oncology platform and elsewhere.

DON'T BUY

No new drugs or trials. Doing nothing interesting. Prefers Eli Lilly.

BUY
It was upgraded today. What an earnings report, and they increased full-year guidance. Their HIV franchise continues to drive the top and bottom lines. Long-term, they continue to expand in oncolocy treatments--their pipeline looks fine.
BUY
Likes healthcare. This pays a 4.5% dividend yield, because of the strength of their drugs. Likes their huge pipeline of drugs, spanning cell therapy, oncology and HIV. They just beat top and bottom lines and raised their 2022 guidance.
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.
Showing 1 to 15 of 264 entries

Gilead Sciences Inc.(GILD-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 4

Stockchase rating for Gilead Sciences Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Gilead Sciences Inc.(GILD-Q) Frequently Asked Questions

What is Gilead Sciences Inc. stock symbol?

Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q

Is Gilead Sciences Inc. a buy or a sell?

In the last year, 4 stock analysts published opinions about GILD-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Gilead Sciences Inc..

Is Gilead Sciences Inc. a good investment or a top pick?

Gilead Sciences Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Gilead Sciences Inc..

Why is Gilead Sciences Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Gilead Sciences Inc. worth watching?

4 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.

What is Gilead Sciences Inc. stock price?

On 2025-04-02, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $111.89.